{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:25:31Z","timestamp":1786879531961,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:21:52Z","timestamp":1784114512000},"page":"660-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry"],"prefix":"10.1016","volume":"182","author":[{"given":"S.","family":"Ferrao-Malheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neurol.2026.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"24","year":"2025","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.006_bib0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","article-title":"Unmet needs in preventive treatment of migraine","volume":"12","author":"Bentivegna","year":"2023","journal-title":"Neurol Ther"},{"issue":"11","key":"10.1016\/j.neurol.2026.05.006_bib0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults","volume":"23","author":"Dorosch","year":"2019","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.006_bib0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pneurobio.2009.07.005","article-title":"Pathophysiological basis of migraine prophylaxis","volume":"89","author":"Galletti","year":"2009","journal-title":"Prog Neurobiol"},{"issue":"8","key":"10.1016\/j.neurol.2026.05.006_bib0190","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0002-9343(02)01100-2","article-title":"Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis","volume":"112","author":"Etminan","year":"2002","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.neurol.2026.05.006_bib0195","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.19005","article-title":"Candesartan cilexetil: an angiotensin II receptor blocker","volume":"33","author":"Stoukides","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0006-8993(00)02377-5","article-title":"Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors","volume":"871","author":"Nishimura","year":"2000","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.neurol.2026.05.006_bib0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1291\/hypres.27.441","article-title":"Efficacy of candesartan in the treatment of migraine in hypertensive patients","volume":"27","author":"Owada","year":"2004","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial","volume":"289","author":"Tronvik","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.neurol.2026.05.006_bib0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study","volume":"34","author":"Stovner","year":"2014","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.neurol.2026.05.006_bib0220","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1474-4422(25)00269-8","article-title":"Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial","volume":"24","author":"\u00d8ie","year":"2025","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2026.05.006_bib0225","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00415-020-09989-9","article-title":"Candesartan in migraine prevention: results from a retrospective real-world study","volume":"267","author":"Messina","year":"2020","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0230","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41598-021-83508-2","article-title":"Real world effectiveness and tolerability of Candesartan in the treatment of migraine: a retrospective cohort study","volume":"11","author":"Sanchez-Rodriguez","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.neurol.2026.05.006_bib0235","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241248833","article-title":"CandeSpartan study: Candesartan Spanish response-prediction and tolerability study in migraine","volume":"44","author":"Garcia-Azorin","year":"2024","journal-title":"Cephalalgia"},{"issue":"17","key":"10.1016\/j.neurol.2026.05.006_bib0240","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurol.2026.05.006_bib0245","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2026.05.006_bib0250","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0042-1755320","article-title":"Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II","volume":"80","author":"Santos","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.neurol.2026.05.006_bib0255","first-page":"1","article-title":"Updated Canadian Headache Society migraine prevention guideline with systematic review and meta-analysis","author":"Medrea","year":"2024","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"10.1016\/j.neurol.2026.05.006_bib0260","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume":"45","author":"Ornello","year":"2025","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.neurol.2026.05.006_bib0265","doi-asserted-by":"crossref","first-page":"208e1","DOI":"10.1016\/j.medcli.2024.02.006","volume":"163","author":"Belvis","year":"2024","journal-title":"Med Clin"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0270","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-019-1060-6","article-title":"Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine","volume":"20","author":"Kouremenos","year":"2019","journal-title":"J Headache Pain"},{"issue":"7","key":"10.1016\/j.neurol.2026.05.006_bib0275","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neurol.2021.07.006","article-title":"Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment","volume":"177","author":"Ducros","year":"2021","journal-title":"Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.006_bib0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10194-009-0182-7","article-title":"receptor antagonists against migraine in pregnancy: fatal outcome","volume":"11","author":"Haaland","year":"2010","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s10194-023-01680-4","article-title":"One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study","volume":"24","author":"Lanteri-Minet","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0290","first-page":"1","article-title":"Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache","year":"2018","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.neurol.2026.05.006_bib0295","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"10.1016\/j.neurol.2026.05.006_bib0300","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: the HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"issue":"9596","key":"10.1016\/j.neurol.2026.05.006_bib0305","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.05.006_bib0310","doi-asserted-by":"crossref","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","article-title":"Chronic migraine pathophysiology and treatment: a review of current perspectives","volume":"2","author":"Mungoven","year":"2021","journal-title":"Front Pain Res"},{"issue":"12","key":"10.1016\/j.neurol.2026.05.006_bib0315","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","article-title":"Risk factors for migraine disease progression: a narrative review for a patient-centered approach","volume":"270","author":"Lipton","year":"2023","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.006_bib0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"10.1016\/j.neurol.2026.05.006_bib0325","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13760-021-01770-7","article-title":"Pooled retrospective analysis of 70mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice","volume":"122","author":"Storch","year":"2022","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"10.1016\/j.neurol.2026.05.006_bib0330","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251318016","article-title":"Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache","volume":"45","author":"Pozo-Rosich","year":"2025","journal-title":"Cephalalgia"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:45:16Z","timestamp":1786877116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0035378726005588"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}